Follow Cellebrite to never miss an important update.
Cellebrite is beginning the process to redomicile, which means it will move its legal headquarters and incorporation from Israel to the United States. While the company already has a large presence in Virginia, this formal move can make the stock easier for more U.S. investment funds to own.
For a company that sells digital investigation tools to government agencies, being a U.S. corporation can also simplify the process of winning large federal contracts. It removes certain regulatory hurdles and perception issues that can sometimes come with being a foreign-domiciled firm in the sensitive public safety and defense sectors.
Source: PRNewsWire
Cellebrite Guardian, the company's cloud-based tool for managing digital evidence, completed an independent security assessment in Australia. It reached the "Protected" level, which is a specific standard required for many Australian government and national security agencies to use cloud software. This is a small but necessary step for Cellebrite to grow its business outside of the U.S. and Israel. By meeting these local security standards, the company makes it easier for international police and defense departments to move their evidence management away from old paper or hard-drive systems and onto Cellebrite's subscription software.
Source: PRNewsWire
A law firm is investigating whether the company violated securities laws, which are the rules meant to protect people from being misled by businesses they invest in. This type of investigation is very common after a stock falls sharply, as lawyers look for any reason to file a class-action lawsuit on behalf of shareholders. While these announcements sound serious, they are a routine part of the market's reaction to bad news. Unless a specific, credible claim of fraud or hidden information emerges, this investigation is unlikely to change the company's long-term value or its ability to sell software to law enforcement agencies.
Cellebrite reported second-quarter earnings of 11 cents per share, which was higher than the 6 cents analysts expected. However, the company lowered its full-year forecast for revenue and annual recurring revenue, a key measure of the predictable subscription income it expects to collect over the next year. This suggests that the transition to its broader software platform might be moving slower than previously thought.
Alongside the results, the company announced that Shiven Ramji is taking over as CEO immediately, replacing Thomas Hogan. While the company described this as a planned move, the combination of a leadership change and a lowered financial outlook led to a sharp 32 percent drop in the stock price. This is a significant setback for a business that has otherwise been a leader in the niche market for digital evidence tools.
D.A. Davidson increased its price target for Cellebrite to $22, which is about 10 percent higher than the average analyst target of $20. This move suggests growing confidence in the company's ability to sell more software to law enforcement agencies.
Cellebrite is currently shifting its business to a subscription model. Higher price targets like this one usually reflect a belief that the company will successfully keep its existing customers while adding new ones in the federal government.
Source: D.A. Davidson
Cellebrite has a habit of clearing the bars set by analysts, beating profit estimates in six of the last eight quarters while growing its recurring revenue at a steady clip.
| Expectation | |
|---|---|
| EPS | $0.17 |
| Revenue | $146M |